A Phase 3 interventional study of Dupilumab and Placebo in Atopic Dermatitis, sponsored by Sanofi. Completed at 27 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-19.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing dupilumab in Dermatitis, Atopic — 4 open to participants now, 6 under way, none of them phase 3. dupilumab · Dermatitis, Atopic.
Among the 50 studies testing dupilumab in Dermatitis, Atopic, this one is the 20th largest by enrollment, is one of 5 that started in 2018, is one of 11 in phase 3, and was the 24th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →4 of the 50 studies testing dupilumab in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:
Northwestern University · Sites in United States
Ages 6–17
University of California, San Francisco · Sites in United States
Ages 18+
University of Michigan · Sites in United States
Ages 18+
Sanofi
Ages 18+
By country, each count listing its studies:
dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, dupilumab is the treatment under test here. Read study by study →
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8 · Phase 3 12 · Phase 4 24
First in 2011; this study’s year is marked. 5 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 165 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 75 across the 50 interventional studies. Of the 38 that completed or were terminated, 26 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 50 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
43 studies in Dermatitis, Atopic by Sanofi: 5 open now, 16 under way, 4 of them phase 3. Of 26 finished, 9 (35%) have results posted.
Among the 43 studies in Dermatitis, Atopic by Sanofi, this one is the 11th largest by enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2018, is one of 8 in phase 3, and was the 5th registered.
Sanofi’s Dermatitis, Atopic studies by the year they started, since 2006.
4 of the studies testing dupilumab in Dermatitis, Atopic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07905547SanofiA Study to Investigate Dupixent/ Dupilumab in Adult Indian Participants With Moderate-to-severe Atopic Dermatitis | 2027-02-07 |
| NCT05983068SanofiA Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis | 2027-04-29 |
| NCT05042258Northwestern UniversityUsing Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis | 2027-06 |
| NCT05268107University of MichiganEthnic Differences in Mechanisms of Action of Dupilumab | 2027-07 |
Add all 4 to your calendar (.ics) → With an account.
Among the 50 studies testing dupilumab in Dermatitis, Atopic, from their registry updates:
Among Sanofi’s 43 in Dermatitis, Atopic:
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To evaluate the efficacy of dupilumab monotherapy compared to placebo treatment in adult participants with moderate-to-severe atopic dermatitis (AD).
Secondary Objectives:
The maximum study duration was 33 weeks per participants, including a screening period of up to 5 weeks, a 16-week randomized treatment period, and a 12-week follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Had used any of the following treatments within 4 weeks before the baseline visit, or any condition that, in the opinion of the investigator, was likely to require such treatment(s) during the first 4 weeks of study treatment:
Treatment with biologics as follows:
The above information was not intended to contain all considerations relevant to a participants potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo matched to dupilumab 600 milligrams (mg) (loading dose), subcutaneously (SC) on Day 1 followed by placebo matched to dupilumab 300 mg once every 2 weeks (Q2W) for 16 weeks.
Drug: Placebo · Drug: Emollient (moisturizer)
Dupilumab at a loading dose of 600 mg, SC on Day 1 followed by 300 mg, Q2W for 16 weeks.
Drug: Dupilumab · Drug: Emollient (moisturizer)
Pharmaceutical form: solution, Route of administration: SC
Also known as: Dupixent, SAR231893
Pharmaceutical form: solution, Route of administration: SC
Pharmaceutical form: cream, Route of administration: topical use
Number of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" and Reduction From Baseline of Greater Than or Equal to (>=) 2 Points at Week 16
The IGA is an assessment instrument used to rate the severity of AD globally based on a 5-point scale ranging from (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe), higher score indicated higher severity.
Time frame: Baseline, Week 16
Number of Participants With Eczema Area and Severity Index (EASI) - 75 Response (>= 75% Reduction in Score From Baseline) at Week 16
EASI: Measure to assess severity and extent of AD based on 4 AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\] and lichenification). Each characteristic was assessed for severity by Investigator/designee on scale of "0" (absent) through "3" (severe) and scored separately for each of 4 body regions (head, trunk, upper and lower extremities). Total score range from 0 (minimum) to 72 (maximum), higher scores indicated greater severity of AD.
Time frame: Baseline, Week 16
Number of Participants Who Achieved >=4 Points With Reduction From Baseline in Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score at Week 16
Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]), higher scores indicated greater severity.
Time frame: Baseline, Week 16
Number of Participants Who Achieved >=3 Points With Reduction From Baseline in Weekly Average of Peak Daily Pruritus Numerical Rating Scale Score at Week 16
Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]), higher scores indicated greater severity.
Time frame: Baseline, Week 16
Percentage Change From Baseline at Week 16 in Weekly Average of Peak Daily Pruritus NRS
Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]), higher scores indicated greater severity.
Time frame: Baseline, Week 16
Change From Baseline at Week 16 in Weekly Average of Peak Daily Pruritus NRS
Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]), higher scores indicated greater severity.
Time frame: Baseline, Week 16
Percentage Change From Baseline to Week 16 in EASI Score
EASI: Measure to assess severity \& extent of AD based on 4 AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\] \& lichenification). Each characteristic was assessed for severity by Investigator/designee on scale of "0" (absent) through "3"(severe) \& scored separately for each of 4 body regions (head, trunk, upper \& lower extremities). Total score ranges from 0 (minimum) to 72 (maximum), higher scores indicated greater severity of AD.
Time frame: Baseline to Week 16
Change From Baseline to Week 16 in Percent Body Surface Area (BSA) of AD Involvement
BSA affected by AD was assessed for each section of the body (the possible highest score for each region was: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]) and reported as a percentage of all major body sections combined. The reported percentage of BSA was combined percentage of all major body sections.
Time frame: Baseline to Week 16
Change From Baseline to Week 16 in Dermatology Life Quality Index (DLQI) Total Score
The DLQI was a validated questionnaire used to measure the impact of AD disease symptoms and treatment on health-related quality of life (QOL). DLQI consisting of a set of 10 questions which assess QOL over the past week. Responses to each questions were assessed on a scale of 0 to 3, where 0 is "not at all" and 3 is "very much". Scores from all 10 questions added up to give total DLQI scores ranged from 0 (not at all) to 30 (very much), higher scores indicated more impact on quality of life.
Time frame: Baseline to Week 16
Change From Baseline to Week 16 in Patient Oriented Eczema Measure (POEM)
The POEM is a 7-item self-assessment questionnaire that assesses disease symptoms on a scale ranging from 0 to 4 (0 = no days, 1 = 1 to 2 days, 2 = 3 to 4 days, 3 = 5 to 6 days, 4 = all days). The sum of the 7 items gives the total POEM score of 0 (absent disease) to 28 (severe disease). Higher scores indicated more severe disease and poor quality of life.
Time frame: Baseline to Week 16
Percentage Change From Baseline to Week 2 in Weekly Average of Peak Daily Pruritus NRS
Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]), higher scores indicated greater severity.
Time frame: Baseline to Week 2
Percentage Change From Baseline to Week 16 in EuroQoL Five Dimensions Questionnaire (EQ-5D) Index Scores
The EQ-5D is a standardized measure of health status which is consists of 2 parts; the descriptive system and the EQ visual analogue scale (EQVAS). The EQ-5D descriptive system includes 5 dimensions; mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension measured on 3 levels: "no problem" (level 1), "some problems" (level 2), "extreme problems" (level 3). The digits for 5 dimensions can be combined in a 5-digit number describing the respondent's health state. The 5 dimensional 3-level systems was converted into single index utility score between 0 to 1 that quantify health status, where 0 represents "death" and 1 represents "perfect health".
Time frame: Baseline to Week 16
Percentage Change From Baseline to Week 16 in EuroQoL Five Dimensions Questionnaire Visual Analog Scale Scores
The EQ-5D VAS records the respondent's self-rated health on a vertical, visual analogue scale ranged from 0-100 where 100 indicated "best imaginable health state" and 0 indicated "worst imaginable health state", higher scores indicated better outcome.
Time frame: Baseline to Week 16
Absolute Change From Baseline to Week 16 in EQ-5D Index Scores
The EQ-5D is a standardized measure of health status which consisted of 2 parts; the descriptive system and the EQVAS. The EQ-5D descriptive system includes 5 dimensions; mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension measured on 3 levels: "no problem" (level 1), "some problems" (level 2), "extreme problems" (level 3). The digits for 5 dimensions can be combined in a 5-digit number describing the respondent's health state. The 5 dimensional 3-level systems was converted into single index utility score between 0 to 1 that quantify health status, where 0 represents "death" and 1 represents "perfect health".
Time frame: Baseline to Week 16
Absolute Change From Baseline to Week 16 in EuroQoL Five Dimensions Questionnaire Visual Analog Scale Scores
The EQ-5D VAS records the respondent's self-rated health on a vertical, visual analogue scale ranged from 0-100 where 100 indicated "best imaginable health state" and 0 indicated "worst imaginable health state", higher scores indicated better outcome.
Time frame: Baseline to Week 16
Number of Participants Who Achieve Reduction of IGA Score by >=2 From Baseline to Week 16
The IGA is an assessment instrument used to rate the severity of AD globally, based on a 5-point scale ranging from (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe), higher score indicated higher severity. In this outcome measure, number of participants who achieved reduction from baseline of \>=2 points in IGA score at Week 16 were reported.
Time frame: Baseline to Week 16
Number of Participants Achieving IGA 0 to 1 and a Reduction of >=2 Points From Baseline Through Week 16
The IGA is an assessment instrument used to rate the severity of AD globally based on a 5-point scale ranging from (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe), higher score indicated higher severity.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16
Absolute Change in EASI Score From Baseline at Weeks 2, 4, 8, 12 and 16
EASI: Measure to assess severity \& extent of AD based on 4 AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\] \& lichenification). Each characteristic was assessed for severity by Investigator/designee on scale of "0" (absent) through "3" (severe) \& scored separately for each of 4 body regions (head, trunk, upper \& lower extremities). Total score range from 0 (minimum) to 72 (maximum), higher scores indicated greater severity of AD. Participants with missing EASI Score at each visit were imputed using MI (Multiple Imputation) method.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16
Percentage Change in EASI Score From Baseline at Weeks 2, 4, 8, 12 and 16
EASI: Measure to assess severity \& extent of AD based on 4 AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\] \& lichenification). Each characteristic was assessed for severity by Investigator/designee on scale of "0" (absent) through "3" (severe) \& scored separately for each of 4 body regions (head, trunk, upper \& lower extremities). Total score range from 0 (minimum) to 72 (maximum), higher scores indicated greater severity of AD.
Time frame: Baseline, Week 2, Week 4, Week 8, Week 12, Week 16
Number of Participants With EASI-50 (>=50% Improvement From Baseline) at Week 16
EASI: Measure to assess severity \& extent of AD based on 4 AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\] \& lichenification). Each characteristic was assessed for severity by Investigator/designee on scale of "0" (absent) through "3" (severe) \& scored separately for each of 4 body regions (head, trunk, upper \& lower extremities). Total score range from 0 (minimum) to 72 (maximum), higher scores indicated greater severity of AD.
Time frame: Baseline, Week 16
Number of Participants With EASI-90 (>=90% Improvement From Baseline) at Week 16
EASI: Measure to assess severity \& extent of AD based on 4 AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\] \& lichenification). Each characteristic was assessed for severity by Investigator/designee on scale of "0" (absent) through "3" (severe) \& scored separately for each of 4 body regions (head, trunk, upper \& lower extremities). Total score range from 0 (minimum) to 72 (maximum), higher scores indicated greater severity of AD.
Time frame: Baseline, Week 16
Absolute Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16
Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]), higher scores indicated greater severity. Participants with missing Peak Daily Pruritus NRS Score at each visit were imputed using MI method.
Time frame: From Baseline Through Week 16
Percentage Change in Weekly Average of Peak Daily Pruritus NRS Score From Baseline Through Week 16
Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]), higher scores indicated greater severity. Participants with missing peak NRS scores at each visit were imputed using MI method.
Time frame: From Baseline Through Week 16
Number of Participants Who Responded "Absence of Pruritus" or "Mild Pruritus" in the Pruritus Categorical Scale at Week 16
The pruritus categorical scale was a 4-point scale used to assess symptoms of AD. The scale is rated as follows: 0: absence of pruritus; 1: mild pruritus (occasional slight itching/scratching); 2: moderate pruritus (constant or intermittent itching/scratching that does not disturb sleep) and 3: severe pruritus (bothersome itching/scratching that disturbs sleep), higher scores indicated worse outcome.
Time frame: Week 16
Number of Days of Sick Leave/Missed School Days
Participants who were employed or enrolled in school for full time were asked to report the number of sick leave/missed school days since the last study assessment. Participants were counted as Full time if the participant checked "Full time" at all visits through 16-week treatment period and participants were counted as Part time if the participant checked at least one "Part time" during 16-week treatment period.
Time frame: Week 16
Percentage of Participants With at Least One Day Sick Leave/Missed School Days
Participants who were employed or enrolled in school for full time were asked to report the number of sick leave/missed school days since the last study assessment. Participants were counted as Full time if the participant checked "Full time" at all visits through 16-week treatment period and participants were counted as Part time if the participant checked at least one "Part time" during 16-week treatment period.
Time frame: Week 16
The study was conducted at 25 active centers in China between 19 Dec 2018 and 14 Feb 2020. A total of 165 participants were randomized and treated in the study.
| Milestone | Placebo Q2W | Dupilumab 300 mg Q2W |
|---|---|---|
| Started | 83 | 82 |
| Completed | 66 | 76 |
| Not completed | 17 | 6 |
| Withdrew: Adverse event (ae) | 2 | 4 |
| Withdrew: Lack of efficacy | 4 | 1 |
| Withdrew: Withdrawal by subject | 11 | 1 |
The IGA is an assessment instrument used to rate the severity of AD globally based on a 5-point scale ranging from (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe), higher score indicated higher severity.
| Participants | Placebo Q2W | Dupilumab 300 mg Q2W |
|---|---|---|
| Number of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" and Reduction From Baseline of Greater Than or Equal to (>=) 2 Points at Week 16 | 4 | 22 |
EASI: Measure to assess severity and extent of AD based on 4 AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\] and lichenification). Each characteristic was assessed for severity by Investigator/designee on scale of "0" (absent) through "3" (severe) and scored separately for each of 4 body regions (head, trunk, upper and lower extremities). Total score range from 0 (minimum) to 72 (maximum), higher scores indicated greater severity of AD.
| Participants | Placebo Q2W | Dupilumab 300 mg Q2W |
|---|---|---|
| Number of Participants With Eczema Area and Severity Index (EASI) - 75 Response (>= 75% Reduction in Score From Baseline) at Week 16 | 12 | 47 |
Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]), higher scores indicated greater severity.
| Participants | Placebo Q2W | Dupilumab 300 mg Q2W |
|---|---|---|
| Number of Participants Who Achieved >=4 Points With Reduction From Baseline in Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score at Week 16 | 4 | 32 |
Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]), higher scores indicated greater severity.
| Participants | Placebo Q2W | Dupilumab 300 mg Q2W |
|---|---|---|
| Number of Participants Who Achieved >=3 Points With Reduction From Baseline in Weekly Average of Peak Daily Pruritus Numerical Rating Scale Score at Week 16 | 8 | 43 |
Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]), higher scores indicated greater severity.
| percentage change | Placebo Q2W | Dupilumab 300 mg Q2W |
|---|---|---|
| Percentage Change From Baseline at Week 16 in Weekly Average of Peak Daily Pruritus NRS | -21.13 ± 3.610 | -48.59 ± 3.026 |
Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]), higher scores indicated greater severity.
| units on a scale | Placebo Q2W | Dupilumab 300 mg Q2W |
|---|---|---|
| Change From Baseline at Week 16 in Weekly Average of Peak Daily Pruritus NRS | -1.64 ± 0.272 | -3.84 ± 0.237 |
EASI: Measure to assess severity \& extent of AD based on 4 AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\] \& lichenification). Each characteristic was assessed for severity by Investigator/designee on scale of "0" (absent) through "3"(severe) \& scored separately for each of 4 body regions (head, trunk, upper \& lower extremities). Total score ranges from 0 (minimum) to 72 (maximum), higher scores indicated greater severity of AD.
| percentage change | Placebo Q2W | Dupilumab 300 mg Q2W |
|---|---|---|
| Percentage Change From Baseline to Week 16 in EASI Score | -39.44 ± 4.936 | -75.23 ± 3.879 |
BSA affected by AD was assessed for each section of the body (the possible highest score for each region was: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]) and reported as a percentage of all major body sections combined. The reported percentage of BSA was combined percentage of all major body sections.
| percentage of body surface area | Placebo Q2W | Dupilumab 300 mg Q2W |
|---|---|---|
| Change From Baseline to Week 16 in Percent Body Surface Area (BSA) of AD Involvement | -19.25 ± 2.557 | -37.76 ± 2.126 |
The DLQI was a validated questionnaire used to measure the impact of AD disease symptoms and treatment on health-related quality of life (QOL). DLQI consisting of a set of 10 questions which assess QOL over the past week. Responses to each questions were assessed on a scale of 0 to 3, where 0 is "not at all" and 3 is "very much". Scores from all 10 questions added up to give total DLQI scores ranged from 0 (not at all) to 30 (very much), higher scores indicated more impact on quality of life.
| units on a scale | Placebo Q2W | Dupilumab 300 mg Q2W |
|---|---|---|
| Change From Baseline to Week 16 in Dermatology Life Quality Index (DLQI) Total Score | -5.06 ± 0.701 | -10.33 ± 0.625 |
The POEM is a 7-item self-assessment questionnaire that assesses disease symptoms on a scale ranging from 0 to 4 (0 = no days, 1 = 1 to 2 days, 2 = 3 to 4 days, 3 = 5 to 6 days, 4 = all days). The sum of the 7 items gives the total POEM score of 0 (absent disease) to 28 (severe disease). Higher scores indicated more severe disease and poor quality of life.
| units on a scale | Placebo Q2W | Dupilumab 300 mg Q2W |
|---|---|---|
| Change From Baseline to Week 16 in Patient Oriented Eczema Measure (POEM) | -4.04 ± 0.788 | -12.89 ± 0.685 |
Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]), higher scores indicated greater severity.
| percentage change | Placebo Q2W | Dupilumab 300 mg Q2W |
|---|---|---|
| Percentage Change From Baseline to Week 2 in Weekly Average of Peak Daily Pruritus NRS | -4.75 ± 1.802 | -15.65 ± 1.818 |
The EQ-5D is a standardized measure of health status which is consists of 2 parts; the descriptive system and the EQ visual analogue scale (EQVAS). The EQ-5D descriptive system includes 5 dimensions; mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension measured on 3 levels: "no problem" (level 1), "some problems" (level 2), "extreme problems" (level 3). The digits for 5 dimensions can be combined in a 5-digit number describing the respondent's health state. The 5 dimensional 3-level systems was converted into single index utility score between 0 to 1 that quantify health status, where 0 represents "death" and 1 represents "perfect health".
| percentage change | Placebo Q2W | Dupilumab 300 mg Q2W |
|---|---|---|
| Percentage Change From Baseline to Week 16 in EuroQoL Five Dimensions Questionnaire (EQ-5D) Index Scores | 2.92 ± 0.692 | 8.00 ± 0.562 |
The EQ-5D VAS records the respondent's self-rated health on a vertical, visual analogue scale ranged from 0-100 where 100 indicated "best imaginable health state" and 0 indicated "worst imaginable health state", higher scores indicated better outcome.
| percentage change | Placebo Q2W | Dupilumab 300 mg Q2W |
|---|---|---|
| Percentage Change From Baseline to Week 16 in EuroQoL Five Dimensions Questionnaire Visual Analog Scale Scores | 60.19 ± 25.154 | 90.32 ± 24.775 |
The EQ-5D is a standardized measure of health status which consisted of 2 parts; the descriptive system and the EQVAS. The EQ-5D descriptive system includes 5 dimensions; mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension measured on 3 levels: "no problem" (level 1), "some problems" (level 2), "extreme problems" (level 3). The digits for 5 dimensions can be combined in a 5-digit number describing the respondent's health state. The 5 dimensional 3-level systems was converted into single index utility score between 0 to 1 that quantify health status, where 0 represents "death" and 1 represents "perfect health".
| units on a scale | Placebo Q2W | Dupilumab 300 mg Q2W |
|---|---|---|
| Absolute Change From Baseline to Week 16 in EQ-5D Index Scores | 0.02 ± 0.006 | 0.06 ± 0.004 |
The EQ-5D VAS records the respondent's self-rated health on a vertical, visual analogue scale ranged from 0-100 where 100 indicated "best imaginable health state" and 0 indicated "worst imaginable health state", higher scores indicated better outcome.
| units on a scale | Placebo Q2W | Dupilumab 300 mg Q2W |
|---|---|---|
| Absolute Change From Baseline to Week 16 in EuroQoL Five Dimensions Questionnaire Visual Analog Scale Scores | 10.75 ± 2.689 | 18.22 ± 2.243 |
The IGA is an assessment instrument used to rate the severity of AD globally, based on a 5-point scale ranging from (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe), higher score indicated higher severity. In this outcome measure, number of participants who achieved reduction from baseline of \>=2 points in IGA score at Week 16 were reported.
| Participants | Placebo Q2W | Dupilumab 300 mg Q2W |
|---|---|---|
| Number of Participants Who Achieve Reduction of IGA Score by >=2 From Baseline to Week 16 | 7 | 39 |
The IGA is an assessment instrument used to rate the severity of AD globally based on a 5-point scale ranging from (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe), higher score indicated higher severity.
| Participants | Placebo Q2W | Dupilumab 300 mg Q2W |
|---|---|---|
| Week 2 | 0 | 2 |
| Week 4 | 0 | 6 |
| Week 8 | 0 | 9 |
| Week 12 | 4 | 16 |
| Week 16 | 4 | 22 |
EASI: Measure to assess severity \& extent of AD based on 4 AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\] \& lichenification). Each characteristic was assessed for severity by Investigator/designee on scale of "0" (absent) through "3" (severe) \& scored separately for each of 4 body regions (head, trunk, upper \& lower extremities). Total score range from 0 (minimum) to 72 (maximum), higher scores indicated greater severity of AD. Participants with missing EASI Score at each visit were imputed using MI (Multiple Imputation) method.
| units on a scale | Placebo Q2W | Dupilumab 300 mg Q2W |
|---|---|---|
| Week 2 | -3.27 ± 7.974 | -12.48 ± 12.640 |
| Week 4 | -6.45 ± 11.838 | -19.56 ± 13.687 |
| Week 8 | -9.54 ± 10.947 | -22.45 ± 12.830 |
| Week 12 | -11.23 ± 12.603 | -24.32 ± 14.191 |
| Week 16 | -12.60 ± 12.484 | -25.87 ± 13.985 |
EASI: Measure to assess severity \& extent of AD based on 4 AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\] \& lichenification). Each characteristic was assessed for severity by Investigator/designee on scale of "0" (absent) through "3" (severe) \& scored separately for each of 4 body regions (head, trunk, upper \& lower extremities). Total score range from 0 (minimum) to 72 (maximum), higher scores indicated greater severity of AD.
| percentage change | Placebo Q2W | Dupilumab 300 mg Q2W |
|---|---|---|
| Week 2 | -10.55 ± 2.977 | -35.69 ± 2.930 |
| Week 4 | -19.28 ± 3.981 | -55.83 ± 3.684 |
| Week 8 | -29.38 ± 4.147 | -65.84 ± 3.562 |
| Week 12 | -35.26 ± 4.674 | -70.36 ± 4.047 |
| Week 16 | -39.44 ± 4.936 | -75.23 ± 3.879 |
EASI: Measure to assess severity \& extent of AD based on 4 AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\] \& lichenification). Each characteristic was assessed for severity by Investigator/designee on scale of "0" (absent) through "3" (severe) \& scored separately for each of 4 body regions (head, trunk, upper \& lower extremities). Total score range from 0 (minimum) to 72 (maximum), higher scores indicated greater severity of AD.
| Participants | Placebo Q2W | Dupilumab 300 mg Q2W |
|---|---|---|
| Number of Participants With EASI-50 (>=50% Improvement From Baseline) at Week 16 | 24 | 58 |
EASI: Measure to assess severity \& extent of AD based on 4 AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\] \& lichenification). Each characteristic was assessed for severity by Investigator/designee on scale of "0" (absent) through "3" (severe) \& scored separately for each of 4 body regions (head, trunk, upper \& lower extremities). Total score range from 0 (minimum) to 72 (maximum), higher scores indicated greater severity of AD.
| Participants | Placebo Q2W | Dupilumab 300 mg Q2W |
|---|---|---|
| Number of Participants With EASI-90 (>=90% Improvement From Baseline) at Week 16 | 5 | 33 |
Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]), higher scores indicated greater severity. Participants with missing Peak Daily Pruritus NRS Score at each visit were imputed using MI method.
| units on a scale | Placebo Q2W | Dupilumab 300 mg Q2W |
|---|---|---|
| Week 1 | -0.26 ± 0.106 | -0.63 ± 0.107 |
| Week 2 | -0.38 ± 0.135 | -1.26 ± 0.136 |
| Week 3 | -0.61 ± 0.153 | -1.90 ± 0.153 |
| Week 4 | -0.69 ± 0.162 | -2.26 ± 0.159 |
| Week 5 | -0.88 ± 0.191 | -2.61 ± 0.187 |
| Week 6 | -0.96 ± 0.205 | -2.81 ± 0.201 |
| Week 7 | -0.88 ± 0.214 | -3.14 ± 0.208 |
| Week 8 | -1.04 ± 0.212 | -3.21 ± 0.205 |
| Week 9 | -1.10 ± 0.218 | -3.29 ± 0.209 |
| Week 10 | -1.12 ± 0.221 | -3.38 ± 0.210 |
| Week 11 | -1.24 ± 0.231 | -3.52 ± 0.216 |
| Week 12 | -1.34 ± 0.233 | -3.59 ± 0.213 |
| Week 13 | -1.46 ± 0.246 | -3.65 ± 0.223 |
| Week 14 | -1.53 ± 0.264 | -3.71 ± 0.241 |
| Week 15 | -1.56 ± 0.262 | -3.81 ± 0.234 |
| Week 16 | -1.64 ± 0.272 | -3.84 ± 0.237 |
Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]), higher scores indicated greater severity. Participants with missing peak NRS scores at each visit were imputed using MI method.
| percentage change | Placebo Q2W | Dupilumab 300 mg Q2W |
|---|---|---|
| Week 1 | -2.95 ± 1.387 | -7.30 ± 1.405 |
| Week 2 | -4.75 ± 1.802 | -15.65 ± 1.818 |
| Week 3 | -7.92 ± 2.000 | -23.66 ± 1.988 |
| Week 4 | -9.10 ± 2.118 | -28.17 ± 2.069 |
| Week 5 | -11.56 ± 2.477 | -32.65 ± 2.410 |
| Week 6 | -12.41 ± 2.623 | -35.01 ± 2.543 |
| Week 7 | -11.37 ± 2.743 | -39.16 ± 2.642 |
| Week 8 | -13.22 ± 2.710 | -40.36 ± 2.594 |
| Week 9 | -14.03 ± 2.796 | -41.28 ± 2.655 |
| Week 10 | -14.24 ± 2.857 | -42.51 ± 2.682 |
| Week 11 | -15.72 ± 2.972 | -44.26 ± 2.746 |
| Week 12 | -17.07 ± 3.048 | -45.37 ± 2.735 |
| Week 13 | -18.80 ± 3.235 | -46.15 ± 2.845 |
| Week 14 | -19.63 ± 3.501 | -47.04 ± 3.061 |
| Week 15 | -19.96 ± 3.503 | -48.29 ± 3.009 |
| Week 16 | -21.13 ± 3.610 | -48.59 ± 3.026 |
The pruritus categorical scale was a 4-point scale used to assess symptoms of AD. The scale is rated as follows: 0: absence of pruritus; 1: mild pruritus (occasional slight itching/scratching); 2: moderate pruritus (constant or intermittent itching/scratching that does not disturb sleep) and 3: severe pruritus (bothersome itching/scratching that disturbs sleep), higher scores indicated worse outcome.
| Participants | Placebo Q2W | Dupilumab 300 mg Q2W |
|---|---|---|
| Number of Participants Who Responded "Absence of Pruritus" or "Mild Pruritus" in the Pruritus Categorical Scale at Week 16 | 12 | 49 |
Participants who were employed or enrolled in school for full time were asked to report the number of sick leave/missed school days since the last study assessment. Participants were counted as Full time if the participant checked "Full time" at all visits through 16-week treatment period and participants were counted as Part time if the participant checked at least one "Part time" during 16-week treatment period.
| Days | Placebo Q2W | Dupilumab 300 mg Q2W |
|---|---|---|
| Full time | 0.66 ± 2.075 | 0.88 ± 3.468 |
| Part time | 11.14 ± 20.923 | 7.44 ± 9.202 |
Participants who were employed or enrolled in school for full time were asked to report the number of sick leave/missed school days since the last study assessment. Participants were counted as Full time if the participant checked "Full time" at all visits through 16-week treatment period and participants were counted as Part time if the participant checked at least one "Part time" during 16-week treatment period.
| percentage of participants | Placebo Q2W | Dupilumab 300 mg Q2W |
|---|---|---|
| Full time | 14.9 | 22.4 |
| Part time | 72.7 | 75.0 |
Collected over All AEs were collected from signature of the informed consent form up to end of study regardless of seriousness or relationship to investigational product. Time frame for reporting of treatment emergent adverse events (TEAEs) was from first dose up to 28 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Q2W | 0/83 (0%) | 4/83 (4.8%) | 57/83 (68.7%) |
| Dupilumab 300 mg Q2W | 0/82 (0%) | 1/82 (1.2%) | 56/82 (68.3%) |
| Event | Placebo Q2W | Dupilumab 300 mg Q2W |
|---|---|---|
| Lung AdenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/83 | 1/82 |
| Anaphylactic ReactionImmune system disorders | 1/83 | 0/82 |
| Connective Tissue DisorderMusculoskeletal and connective tissue disorders | 1/83 | 0/82 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/83 | 0/82 |
| Dermatitis AtopicSkin and subcutaneous tissue disorders | 1/83 | 0/82 |
| Event | Placebo Q2W | Dupilumab 300 mg Q2W |
|---|---|---|
| Dermatitis AtopicSkin and subcutaneous tissue disorders | 41/83 | 36/82 |
| Upper Respiratory Tract InfectionInfections and infestations | 10/83 | 14/82 |
| Protein Urine PresentInvestigations | 9/83 | 9/82 |
| ConjunctivitisInfections and infestations | 4/83 | 8/82 |
| Conjunctivitis AllergicEye disorders | 1/83 | 7/82 |
| NasopharyngitisInfections and infestations | 2/83 | 6/82 |
| FolliculitisInfections and infestations | 6/83 | 1/82 |
| DiarrhoeaGastrointestinal disorders | 2/83 | 5/82 |
| Blood Uric Acid IncreasedInvestigations | 5/83 | 1/82 |
Analysis was performed on Intent-to-treat (ITT) population which consisted of all randomized participants.
| Age, Continuous(years) | Placebo Q2W | Dupilumab 300 mg Q2W | Total |
|---|---|---|---|
| Mean | 30.2 ± 12.46 | 31.0 ± 10.47 | 30.6 ± 11.49 |
| Sex: Female, Male(Participants) | Placebo Q2W | Dupilumab 300 mg Q2W | Total |
|---|---|---|---|
| Female | 23 | 24 | 47 |
| Male | 60 | 58 | 118 |
| Race (NIH/OMB)(Participants) | Placebo Q2W | Dupilumab 300 mg Q2W | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 83 | 82 | 165 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Investigator's Global Assessment (IGA) Score(Participants) | Placebo Q2W | Dupilumab 300 mg Q2W | Total |
|---|---|---|---|
| IGA = 3 | 37 | 35 | 72 |
| IGA = 4 | 46 | 47 | 93 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Dec 2018 to primary completion in Feb 2020, 13 months.
Results were first posted in Apr 2021, 1 year 1 month after primary completion.
Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 13 months is below that.
Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dupilumab